Table 3 IC50 (mM) and MTI% (%) of cell lines after 3-h treatments with ascorbate (AA) and combination where either AA was administered first (AA+LA) or LA was administered first (LA + AA). MTI%: Minimum threshold of inhibition percentage (calculated from the average of lowest three concentrations)
| Â | Cancer lines | Patient-derived Non-SRCC | Patient-derived SRCC | SRCC cell lines | Pancreatic | Ovarian | ||
|---|---|---|---|---|---|---|---|---|
Assays | Reagents | Treatment/Assessment time (hr) | GPM-1 | GPM-2 | HSC-39 | KATO-3 | MIA PaCA-2 | SKOV-3 |
IC50 (mM) | AA | 3/72 | 15.1 ± 2.95 | 14.8 ± 3.92 | 10.6 ± 3.43 | 23.5 ± 8.56 | 9.62 ± 5.27 | 30.4 ± 18.8 |
AA+LA | 3 + 3/72 | 16.5 ± 6.34 | 16.2 ± 6.41 | 14.4 ± 6.28 | 27.6 ± 9.88 | 8.88 ± 5.25 | 31.7 ± 8.11 | |
LA + AA | 3 + 3/72 | 12.6 ± 6.11 | 16.4 ± 4.32 | 8.44 ± 0.79 | 25.2 ± 3.33 | 9.33 ± 4.58 | 33.2 ± 10.5 | |
MTI% (%) | AA | N/A | 20.4 ± 7.44 | 28.5 ± 9.42 | 4.61 ± 3.84 | 17.6 ± 7.24 | 18.6 ± 6.09 | 16.2 ± 3.39 |
AA+LA | N/A | 15.6 ± 11.5 | 14.8 ± 3.90 | 4.97 ± 2.84 | 16.1 ± 7.49 | 12.9 ± 6.08 | 20.8 ± 3.21 | |
LA + AA | N/A | 37.7 ± 5.29 | 27.2 ± 3.56 | 26.0 ± 10.9 | 33.6 ± 8.01 | 23.6 ± 5.44 | 18.9 ± 4.62 | |